Revenue reached $75.8 million for the quarter, climbing from $60.1 million in the same period last year and exceeding the $73.2 million consensus estimate from FactSet. The company posted earnings of $2.3 million, or four cents a share, a sharp turnaround from the $1.1 million loss analysts had anticipated. On an adjusted basis, earnings hit 21 cents a share, comfortably beating the projected 13 cents.

Looking toward 2026, Axogen issued an optimistic outlook with revenue guidance of at least $290 million. This forecast incorporates $7 million from the recent acquisition of BioCircuit. Excluding that deal, the company projects organic growth of at least 26%. The firm also bolstered its balance sheet, reporting cash, restricted cash, and investments of $350.1 million as of September 30, a substantial increase from the $113.4 million held at the end of June.